Announcements
1 July 2024
Journal of Cardiovascular Development and Disease Receives an Updated Impact Factor of 2.4 and CiteScore of 2.6
We are pleased to share that Journal of Cardiovascular Development and Disease (JCDD, ISSN: 2308-3425) was awarded an updated Impact Factor of 2.4 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. Additionally, according to data released by Scopus (Elsevier), JCDD received an increased CiteScore™ of 2.6.
JCDD’s Impact Factor ranks are as follows:
- Q2 (97 out of 220 titles) in the “Cardiac and Cardiovascular Systems” category.
JCDD’s CiteScore ranks are as follows:
- Q2 (31 out of 80 journals) in the “General Pharmacology, Toxicology and Pharmaceutics” category;
- Q3 (167 out of 272 journals) in the “Pharmacology (medical)” category.
|
2.42023 Impact Factor |
97/220 (Q2)Cardiac and Cardiovascular Systems |
2565Citations in 2023 |
|
2.62023 CiteScore |
31/80 (Q2)General Pharmacology, Toxicology and Pharmaceutics |
0.666SNIP |
For further statistics, please visit https://www.mdpi.com/journal/jcdd/stats. For more information about MDPI flagship journals' citation metrics, please see here.
At MDPI, our mission is simple yet powerful: we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.
Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.
JCDD Editorial Office
